{"meta":{"totalResults":4,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"rapamycin"},{"type":"Abbreviation","name":"SLM"},{"type":"USBrandName","name":"Rapamune"},{"type":"ChemicalStructureName","name":"9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2"},{"type":"CodeName","name":"AY 22989"},{"type":"Abbreviation","name":"RAPA"},{"type":"CodeName","name":"SILA 9268A"},{"type":"CodeName","name":"WY-090217"},{"type":"NSCNumber","name":"226080"},{"type":"CASRegistryName","name":"53123-88-9"}],"definition":{"html":"A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production.","text":"A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production."},"drugInfoSummaryLink":null,"nciConceptId":"C1212","nciConceptName":"Sirolimus","termId":42555,"name":"sirolimus","firstLetter":"s","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"sirolimus"},{"aliases":[{"type":"Synonym","name":"albumin-bound sirolimus"},{"type":"Synonym","name":"nab-sirolimus"},{"type":"USBrandName","name":"Fyarro"},{"type":"CodeName","name":"ABI-009"},{"type":"Synonym","name":"nab-rapamycin"},{"type":"Synonym","name":"nanoparticle albumin-bound rapamycin"},{"type":"Synonym","name":"sirolimus albumin-bound nanoparticles"},{"type":"Synonym","name":"nanoparticle albumin-bound sirolimus"},{"type":"Synonym","name":"sirolimus albumin-bound particles"}],"definition":{"html":"The macrolide antibiotic rapamycin bound to nanoparticle albumin with immunosuppressant (see sirolimus) and potential antiangiogenic and antineoplastic activities. Rapamycin binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. In turn, inhibition of mTOR may result in the inhibition of the phosphatidylinositol 3 (PI-3) kinase/Akt pathway and vascular endothelial cell growth factor (VEGF) secretion, which may result in decreased tumor cell proliferation and tumor angiogenesis. The binding of water-insoluble rapamycin to nanoparticle albumin permits the albumin-mediated endocytosis of rapamycin by tumor cells and endothelial cells.","text":"The macrolide antibiotic rapamycin bound to nanoparticle albumin with immunosuppressant (see sirolimus) and potential antiangiogenic and antineoplastic activities. Rapamycin binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. In turn, inhibition of mTOR may result in the inhibition of the phosphatidylinositol 3 (PI-3) kinase/Akt pathway and vascular endothelial cell growth factor (VEGF) secretion, which may result in decreased tumor cell proliferation and tumor angiogenesis. The binding of water-insoluble rapamycin to nanoparticle albumin permits the albumin-mediated endocytosis of rapamycin by tumor cells and endothelial cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/sirolimus-protein-bound-particles","text":"Sirolimus Protein-Bound Particles"},"nciConceptId":"C74065","nciConceptName":"Sirolimus Albumin-bound Nanoparticles","termId":583541,"name":"sirolimus protein-bound nanoparticles","firstLetter":"s","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"sirolimus-albumin-bound-nanoparticles"},{"aliases":[{"type":"CodeName","name":"NPC-12Y"},{"type":"CodeName","name":"NPC 12Y"},{"type":"CodeName","name":"NPC12Y"},{"type":"Synonym","name":"topical sirolimus gel NPC-12Y"}],"definition":{"html":"A topical gel formulation containing the macrolide sirolimus (rapamycin), with potential anti-proliferative activity. Upon topical administration of sirolimus topical gel NPC-12Y, sirolimus is internalized by the affected cells in the skin. In turn, sirolimus binds to the immunophilin FK binding protein-12 (FKBP-12) and forms a sirolimus-FKBP-12 complex. This complex binds to and inhibits the activity of the serine/threonine kinase mammalian target of rapamycin (mTOR) and the mTOR-mediated signaling pathways, which reduces cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol-3 (PI3K) kinase-related kinase (PIKK) family, plays an important role in the PI3K/Akt/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.","text":"A topical gel formulation containing the macrolide sirolimus (rapamycin), with potential anti-proliferative activity. Upon topical administration of sirolimus topical gel NPC-12Y, sirolimus is internalized by the affected cells in the skin. In turn, sirolimus binds to the immunophilin FK binding protein-12 (FKBP-12) and forms a sirolimus-FKBP-12 complex. This complex binds to and inhibits the activity of the serine/threonine kinase mammalian target of rapamycin (mTOR) and the mTOR-mediated signaling pathways, which reduces cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol-3 (PI3K) kinase-related kinase (PIKK) family, plays an important role in the PI3K/Akt/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers."},"drugInfoSummaryLink":null,"nciConceptId":"C190151","nciConceptName":"Sirolimus Topical Gel NPC-12Y","termId":810554,"name":"sirolimus topical gel NPC-12Y","firstLetter":"s","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"sirolimus-topical-gel-npc-12y"},{"aliases":[{"type":"CodeName","name":"PTX 022"},{"type":"CodeName","name":"PTX-022"},{"type":"CodeName","name":"PTX022"},{"type":"Synonym","name":"QTORIN (TM) PTX-022"},{"type":"Synonym","name":"QTORIN (TM) rapamycin anhydrous gel"},{"type":"Synonym","name":"topical sirolimus gel PTX-022"}],"definition":{"html":"A topical gel formulation containing the macrolide sirolimus (rapamycin), with potential anti-proliferative and chemopreventive activities. Upon topical administration of sirolimus topical gel PTX-022, sirolimus migrates into the basal keratinocytes and is internalized by the affected cells. In turn, sirolimus binds to the immunophilin FK binding protein-12 (FKBP-12) and forms a sirolimus-FKBP-12 complex. This complex binds to and inhibits the activity of the serine/threonine kinase mammalian target of rapamycin (mTOR) and the mTOR-mediated signaling pathways, which reduces cellular proliferation in mTOR-overexpressing cells. Additionally, by inhibiting mTOR, PTX-022 may inhibit translation of mutant keratin mRNAs and the production of mutant keratins in cells in which mutant keratin genes dysregulate keratinocyte proliferation.","text":"A topical gel formulation containing the macrolide sirolimus (rapamycin), with potential anti-proliferative and chemopreventive activities. Upon topical administration of sirolimus topical gel PTX-022, sirolimus migrates into the basal keratinocytes and is internalized by the affected cells. In turn, sirolimus binds to the immunophilin FK binding protein-12 (FKBP-12) and forms a sirolimus-FKBP-12 complex. This complex binds to and inhibits the activity of the serine/threonine kinase mammalian target of rapamycin (mTOR) and the mTOR-mediated signaling pathways, which reduces cellular proliferation in mTOR-overexpressing cells. Additionally, by inhibiting mTOR, PTX-022 may inhibit translation of mutant keratin mRNAs and the production of mutant keratins in cells in which mutant keratin genes dysregulate keratinocyte proliferation."},"drugInfoSummaryLink":null,"nciConceptId":"C189208","nciConceptName":"Sirolimus Topical Gel PTX-022","termId":810507,"name":"sirolimus topical gel PTX-022","firstLetter":"s","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"sirolimus-topical-gel-ptx-022"}],"links":null}